Zacks Investment Research
16 Jun 2026, 17:46 UTC · 22w ago
InspireMD Posts Positive CGUARDIANS II Data for CGuard Prime TCAR
Impact · against what's priced in
Positive trial data for the CGuard Prime 80 cm implant increases the probability of FDA approval in H2 2026 and provides a path to access 35,000 annual TCAR procedures. This creates a significant catalyst for revenue growth and addressable market expansion for InspireMD.
- NSPR+0.60
No priced-in read yet
- In context
The 100% acute device success rate and lack of major adverse events in the CGUARDIANS II trial support a potential FDA approval in late 2026, opening a market of over 35,000 annual U.S. TCAR procedures.
Read from the article alone

Top 1 mover · tap to explore




